Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma
- 24 October 2009
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 17 (1) , 45-53
Abstract
Improved survival has been reported for diffuse malignant peritoneal mesothelioma (DMPM) treated by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). The significance of lymph node involvement in this disease is still poorly understood. Prospectively collected clinical data on 83 consecutive patients with DMPM undergoing surgical cytoreduction and closed-abdomen HIPEC with cisplatin and doxorubicin were reviewed. Clinically suspicious lymph nodes were submitted to pathological examination. The impact of nodal involvement on survival was assessed by multivariate analysis; 14 clinicopathological control variables were tested. For the overall series, median follow-up was 52 months (range 1-126 months) and 5-year overall survival (OS) was 49.5%. Lymph nodes were submitted to pathological examination in 38 patients, being positive in 11 and negative in 27. Lymph nodes were not clinically suspicious and not sampled in 45 patients. Iliac (n = 7) and paracolic (n = 2) nodes were the most commonly involved nodes. OS was 18.0% for patients with pathologically positive nodes and 82.5% for those with pathologically negative nodes (P = 0.0024). On multivariate analysis, pathologically negative (versus positive/not assessed) nodes [hazard ratio (HR) = 2.81; 95% confidence interval (CI) = 1.12-7.05; P = 0.027], epithelial subtype (HR = 2.93; CI = 1.24-6.95; P = 0.015), mitotic count <or=5/50 high-power microscopic fields (HPF) (HR = 5.34; CI = 1.96-14.54; P = 0.001), and completeness of cytoreduction (HR = 2.06; CI = 1.19-3.56; P = 0.001) correlated with increased OS. Positive nodes (versus negative/not assessed) did not significantly correlate with survival. Pathologically negative nodes (as compared with pathological positive and not assessed), along with pathological and biological features, independently correlated with increased survival following comprehensive treatment. This suggests the need for careful node sampling when performing surgical cytoreduction for DMPM patients.Keywords
This publication has 29 references indexed in Scilit:
- Novel and Existing Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Predictors of Optimal Resectability in Malignant Peritoneal MesotheliomaAnnals of Surgical Oncology, 2009
- Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesotheliomaEuropean Journal of Surgical Oncology, 2006
- Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic PerfusionAnnals of Surgical Oncology, 2006
- Diffuse malignant mesothelioma of the peritoneumCancer, 2005
- Lymph Node Metastasis in Epithelial Malignancies of the Appendix With Peritoneal Dissemination Does Not Reduce Survival in Patients Treated by Cytoreductive Surgery and Perioperative Intraperitoneal ChemotherapyAnnals of Surgical Oncology, 2004
- Lymphatic spread among women with primary peritoneal carcinomaJournal of Surgical Oncology, 2002
- Diffuse malignant epithelial mesotheliomas of the peritoneum in womenCancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesotheliomaJournal of Cancer Research and Clinical Oncology, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958